Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: A multicentric 2004 national PHRC study

International Journal of Oncology

Volumn 41, Issue 1, 2012, Pages 92-104

  Descotes, Françoise ^a   Jézéquel, Pascal ^b   Spyratos, Frédérique ^c   Campion, Loïc ^b   Grenot, Catherine ^a   Lerebours, Florence ^c   Campone, Mario ^b   Guérin Charbonnel, Catherine ^b   Lanoë, Didier ^b   Adams, Marjorie ^a   André, Jean ^a   Carlioz, Antoine ^d   Martin, Pierre Marie ^d   Chassevent, Agnès ^e   Jourdan, Marie Lise ^f   Guette, Catherine ^e   Zanella Cleon, Isabelle ^g   Ricolleau, Gabriel ^b  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b Rene Gauducheau Cancer Center   (France)

^c INSTITUT CURIE   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^e Paul Papin Cancer Center   (France)

^f CHU BRETONNEAU   (France)

^g INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

Author keywords

2D electrophoresis; Biomarkers; Breast cancer; Node negative; Prognosis; Proteomic

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; FERRITIN LIGHT CHAIN; GLUTAMINE AMIDOTRANSFERASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; PROTEIN; PROTEOME; UNCLASSIFIED DRUG; UROKINASE;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; COMPUTER MODEL; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; RETROSPECTIVE STUDY; TANDEM MASS SPECTROMETRY; TUMOR VOLUME; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

ADULT; AGED; AMINO ACID SEQUENCE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GENE EXPRESSION; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDE MAPPING; PROGNOSIS; PROTEOMICS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84862874981     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1456     Document Type: Article

References (58)

1. Fitzgibbons PL, Page DL, Weaver D, et al: Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 966-978, 2000.
2. Adjuvant therapy for breast cancer. In: NIH consensus statement, pp1-35, 2000.
3. Goldhirsch A, Glick JH, Gelber RD, Coates AS and Senn HJ: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19: 3817-3827, 2001. (Pubitemid 32880060)
4. Goldhirsch A, Glick JH, Gelber RD and Senn HJ: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 90: 1601-1608, 1998. (Pubitemid 28523434)
5. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B and Senn HJ: Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21: 3357-3365, 2003. (Pubitemid 46606270)
6. Harbeck N, Kates RE and Schmitt M: Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 20: 1000-1007, 2002. (Pubitemid 34141844)
7. Look MP, van Putten WL, Duffy MJ, et al: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94: 116-128, 2002. (Pubitemid 34121291)
8. Bertucci F, Houlgatte R, Benziane A, et al: Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet 9: 2981-2991, 2000. (Pubitemid 32000771)
9. Bertucci F, Nasser V, Granjeaud S, et al: Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. Hum Mol Genet 11: 863-872, 2002. (Pubitemid 34449774)
10. Van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009, 2002. (Pubitemid 35461656)
11. Van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002. (Pubitemid 34130608)
12. Wang Y, Klijn JG, Zhang Y, et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679, 2005. (Pubitemid 40260888)
13. Ricolleau G, Charbonnel C, Lode L,et al: Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics 6: 1963-1975, 2006.
14. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
15. Bouchet C, Hacene K, Martin PM, et al: Dissemination risk index based on plasminogen activator system components in primary breast cancer. J Clin Oncol 17: 3048-3057, 1999. (Pubitemid 29470632)
16. Descotes F, Riche B, Saez S, et al: Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator. Clin Breast Cancer 8: 168-177, 2008. (Pubitemid 351655932)
17. Rabilloud T: Silver staining of 2-D electrophoresis gels. Methods Mol Biol 112: 297-305, 1999.
18. O'Connell KL and Stults JT: Identification of mouse liver proteins on two-dimensional electrophoresis gels by matrix-assisted laser desorption/ionization mass spectrometry of in situ enzymatic digests. Electrophoresis 18: 349-359, 1997. (Pubitemid 27174419)
19. Tusher VG, Tibshirani R and Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-5121, 2001. (Pubitemid 32397092)
20. Gharahdaghi F, Weinberg CR, Meagher DA, Imai BS and Mische SM: Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: a method for the removal of silver ions to enhance sensitivity. Electrophoresis 20: 601-605, 1999. (Pubitemid 29183427)
21. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
22. Jezequel P, Campone M, Gouraud W, et al: bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat 131: 765-775, 2012.
23. Galea MH, Blamey RW, Elston CE and Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22: 207-219, 1992.
24. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19: 980-991, 2001. (Pubitemid 32176272)
25. Loussouarn D, Campion L, Leclair F, et al: Validation of UBE2C protein as a prognostic marker in node-positive breast cancer. Br J Cancer 101: 166-173, 2009.
26. Wirapati P, Sotiriou C, Kunkel S, et al: Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10: R65, 2008.
27. Boiteux G, Lascombe I, Roche E, et al: A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Int J Cancer 124: 1820-1828, 2009.
28. Jezequel P, Campion L, Spyratos F, et al: Validation of tumour-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumours: a multicentric 2004 national PHRC study. Int J Cancer (Epub ahead of print) doi: 10.1002/ijc.26397, 2011.
29. Hammamieh R, Chakraborty N, Barmada M, Das R and Jett M: Expression patterns of fatty acid binding proteins in breast cancer cells. J Exp Ther Oncol 5: 133-143, 2005. (Pubitemid 41739373)
30. Celis JE, Ostergaard M, Basse B, et al: Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res 56: 4782-4790, 1996. (Pubitemid 26338085)
31. Lambrechts A, van Troys M and Ampe C: The actin cytoskeleton in normal and pathological cell motility. Int J Biochem Cell Biol 36: 1890-1909, 2004. (Pubitemid 38760020)
32. DesMarais V, Macaluso F, Condeelis J and Bailly M: Synergistic interaction between the Arp2/3 complex and cofilin drives stimulated lamellipod extension. J Cell Sci 117: 3499-3510, 2004. (Pubitemid 39206390)
33. Wang LH, Xiang J, Yan M, et al: The mitotic kinase Aurora-A induces mammary cell migration and breast cancer metastasis by activating the Cofilin-F-actin pathway. Cancer Res 70: 9118-9128, 2005.
34. Bignotti E, Tassi RA, Calza S, et al: Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. Am J Obstet Gynecol 196: 245 e241-211, 2007.
35. Jeong JA, Hong SH, Gang EJ, et al: Differential gene expression profiling of human umbilical cord blood-derived mesenchymal stem cells by DNA microarray. Stem Cells 23: 584-593, 2005. (Pubitemid 40478497)
36. Lee YH, Nair S, Rousseau E, et al: Microarray profiling of isolated abdominal subcutaneous adipocytes from obese vs non-obese Pima Indians: increased expression of inflammation-related genes. Diabetologia 48: 1776-1783, 2005. (Pubitemid 41317831)
37. Lu H, Zhang Y, Roberts DD, Osborne CK and Templeton NS: Enhanced gene expression in breast cancer cells in vitro and tumors in vivo. Mol Ther 6: 783-792, 2002. (Pubitemid 36054311)
38. Revillion F, Pawlowski V, Hornez L and Peyrat JP: Glyceraldehyde-3- phosphate dehydrogenase gene expression in human breast cancer. Eur J Cancer 36: 1038-1042, 2000. (Pubitemid 30316430)
39. Valenti MT BF, Dalle Carbonare L, Azzarello G, Zenari S, Zanatta M, Balducci E, Vinante O and Lo Cascio V: The effect of bisphosphonates on gene expression: GAPDH as a housekeeping or a new target gene? BMC Cancer 6: 49, 2006.
40. Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100: 10393-10398, 2003. (Pubitemid 37071889)
41. Ma XJ, Wang Z, Ryan PD, et al: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5: 607-616, 2004. (Pubitemid 38748922)
42. Minn AJ, Gupta GP, Siegel PM, et al: Genes that mediate breast cancer metastasis to lung. Nature 436: 518-524, 2005. (Pubitemid 41112921)
43. Pawitan Y, Bjöhle J, Amler L, et al: Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7: R953-R964, 2005.
44. Weigelt B, Hu Z, He X, et al: Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 65: 9155-9158, 2005. (Pubitemid 41507977)
45. Bild AH, Yao G, Chang JT, et al: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357, 2006. (Pubitemid 43128862)
46. Chin K, DeVries S, Fridlyand J, et al: Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10: 529-541, 2006. (Pubitemid 44854748)
47. Ivshina AV, George J, Senko O, et al: Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66: 10292-10301, 2006. (Pubitemid 44799747)
48. Desmedt C, Piette F, Loi S, et al: Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13: 3207-3214, 2007. (Pubitemid 46944903)
49. Loi S, Haibe-Kains B, Desmedt C, et al: Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25: 1239-1246, 2007. (Pubitemid 46640570)
50. Minn AJ, Gupta GP, Padua D, et al: Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci USA 104: 6740-6745, 2007. (Pubitemid 47175571)
51. Naderi A, Teschendorff AE, Barbosa-Morais NL, et al: A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 26: 1507-1516, 2007. (Pubitemid 46340809)
52. Anders CK, Acharya CR, Hsu DS, et al: Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One 3: e1373, 2008.
53. Chanrion M, Negre V, Fontaine H, et al: A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res 14: 1744-1752, 2008. (Pubitemid 351469459)
54. Loi S, Haibe-Kains B, Desmedt C, et al: Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomic 9: 239, 2008.
55. Schmidt M, Böhm D, von Törne C, et al: The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68: 5405-5413, 2008.
56. Calabrò A, Beissbarth T, Kuner R, et al: Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat 116: 69-77, 2009.
57. Jézéquel P, Campone M, Roché H, et al: A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial. Breast Cancer Res Treat 116: 509-520, 2009.
58. Zhang Y, Sieuwerts AM, McGreevy M, et al: The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat 116: 303-309, 2009.